

COVID-19: A model correlating BCG vaccination to protection from mortality implicates trained immunity - SUPPLEMENTAL DATA, TABLES & NOTES

SUPPLEMENTAL DATA & SUPPLEMENTAL NOTES

Supplemental Tables

1. **Table 1** of 100 countries ranked by mortality data and BCG vaccination status
2. **Table 2** of Multiple time snapshots (Ranked) of COVID-19 deaths in each country vs BCG history
3. **Table 3** of analysis and comparison of BCG vaccination and Oral Polio vaccination ranked for COVID-19 mortality.

Supplemental note accompanying Supplemental Tables


1. For this analysis, we addressed the temporal dimension of the COVID-19 pandemic. This was challenging as there are so few time series data available (e.g. there is only three to four weeks' of mortality data available). For example, on March 14, 2020 there were only 2 deaths in Germany and 5 in the UK. Three days prior, the 4th highest mortality "country" was a cruise ship (population 2600) the Diamond Princess with 6 deaths. China, Italy and Iran had the top 3 highest mortality rankings. At the time of submission of this manuscript on 07 April 2020 Germany has 1810 deaths and the UK has 5373.
2. Ordinarily more data would be needed, to enable (for example) the calculation of the decline in the daily rate of deaths or relative second derivative of total deaths per country. This would more accurately model the severity of the pandemic from a mathematical point of view. However, due to the lack of data volume, this was not possible at present. In short we aimed to "find the asymptote" for each country on our analysis of mortality vs time. This involves two steps, firstly more temporal data must be gathered in order to plot an approximate function with higher confidence (currently we have not achieved this point in terms of data). And secondly using a suitable regression technique, discern the actual function from which we can easily calculate the asymptote using the standard equations. The choice of regression and tools remains open but in general the data should follow a function of the type $f(x) = a / (1 + b c^{-x})$, which is the well known Logistic Function. The key variable we would solve for being "a", the horizontal asymptote or limiting value as it is known in models of resource limited growth. Of course there are many assumptions around this, to be validated further.
3. Based on the above, we employed a simplified approach that used 'snapshot' dates to take into account the start time of the pandemic per country. We analysed data from countries with the most data points available (although some had limited trustworthy data) and the smallest intervals that smoothed out the inconsistent daily reporting from each country's health authority (many countries with significant death numbers were taking 3 days to correct figures due to stretched health workers, death certification processes and government departments).
4. Since there was a time cost for data collection of higher quality BCG usage history (obtained and cross referenced from multiple sources Supplemental Figure 1), we focussed on the top 100 countries with available mortality data.^{1,2} Outliers, both positive and negative were assessed separately. By the end of March only 100 countries (Supplemental Table 1) had reported fatality data. Further analyses at later stages should re-evaluate this assumption as more nations report.
5. We selected our common starting point once total confirmed deaths of COVID-19 for each country reached 0.1 deaths per million inhabitants. This seemingly arbitrary starting point afforded a good balance between; a start time late enough per country to be aware of the pandemic enough to track deaths (e.g. 5 confirmed deaths for a 50 million population), but simultaneously

early enough to include as many countries as possible. This also provided a 3 to 4 week period of data up to the present for enough countries for dynamic temporal patterns to emerge.

Supplemental Note 1

Confounding Factors

1. Multiple efforts are underway, in several countries, that can effectively suppress the spread of the pandemic and act to ultimately lower death rates. Some of these such as testing, tracking and tracing of COVID-19 infected individuals are well reported and have been used with remarkable effectiveness resulting in a strong reduction in deaths per million. Apart from South Korea, Singapore and Taiwan, the extent of this practice is hard to quantify. At this stage in the pandemic no good tools exist to correct for their suppression of fatalities, though backward looking epidemiological models may be able to approximate their effectiveness. These could be incorporated into future models.
2. Some of the published prior art has used World Bank Income data to remove and “clean” some of the data.³ In theory this may remove some noise due to undersampling in poorer countries. However, in the case of BCG vaccination, this has the actual effect of removing signal due to a far greater number of “poorer” countries engaged in BCG vaccination. As mentioned earlier we correct for this by removing populations below 1 million inhabitants, and more significantly focus only on fatalities per million inhabitants (and explain the few outliers separately). Importantly, there are high income countries engaged in BCG vaccination with high quality data that are well along their pandemic paths to enable for good data to be obtained (Japan, South Korea and Taiwan). In addition there are several BCG vaccinating nations where mortality is so low they take a far greater time to pierce the 0.1 per million threshold and for this reason their influence on the mortality per capita analysis dilutes the weight of BCG as a factor. To account for the perception of uneven mortality data collection (especially in the early stages of the pandemic) in Low and Middle Income Countries (LMICs) we performed additional analysis with our model. We used only the top twenty high income countries.² This analysis excluded the suspected confounder of mortality reporting bias in LMICs. Performing this analysis on the top twenty wealthiest countries continued to reveal a strong separation between BCG vaccinated versus unvaccinated countries. See **Supplemental Figure 1**.



Supplemental Figure 1: A number of publications have linked GDP and other economic indicators to BCG vaccination status and COVID-19 mortality. To correct for confounders associated with this we analyzed the countries with the top 20 highest GDP ratios per capita incorporating their BCG vaccination policies and correlating this with COVID-19 mortality. This analysis shows mortality from COVID-19 and GDP are decoupled. BCG vaccination policies continue to effectively separate COVID-19 mortality between unvaccinated versus vaccinated populations, even when accounting for GDP. Two outliers Australia and Ireland occur and are contextualized in Supplementary Note 2.

3. [BCG vaccine compliance](#), (**Supplemental Figure 2**) and the dates on which it was either initiated or stopped are also very important as pitfalls in analysis. Indeed some highly authoritative sources of data such as the [BCG atlas](#) are unable to provide comprehensive data for all countries. To correct for this variable we closely cross-examined the atlas against [WHO](#), World Bank and local data. For example, we scrutinized well [curated datasets](#) (for example recorded deaths, age and prefecture of origin of every Japanese national deceased from COVID-19) and checked this against the date when BCG vaccination first occurred in that prefecture approximately 70 years ago. The data are highly revealing indicating a sharp delineation at the time vaccination begins. Japan began countrywide BCG vaccination in 1951 with BCG vaccination occurring beginning in 1947 in Tokyo and Osaka. Of the all the 458 recorded deaths from COVID-19 in Japan as of May 2, 2020 only 22 are below the age of 60 or ~5%.

4. BCG Vaccine quality and by inference vaccine type (**Supplemental Figure 3**) could also be a confounding factor. In terms of BCG vaccine quality Japan is recognized to possess the best strain of the vaccine. We carefully traced vaccine quality and origin around the world relating it to protection from mortality especially in countries such as Iran which uses a locally produced strain for nearly 40yrs. In the case of Iran individuals above 40yrs old are unvaccinated. This suggests that Iranians over the age of 40yrs old do not benefit themselves directly from having been vaccinated by BCG. Published data from the Chinese CDC has indicated that mortality was greatest in China in populations above the age of 60. Data on the age structure of all COVID-19 victims per country is difficult to obtain. The “flattening of the curve” of the Iran data (see Figure 1) beyond 14 days post 0.1 million fatalities suggests a more rapid attenuation of deaths distinct from other non-BCG vaccinating countries. This hints at protection from mortality in Iran and elsewhere could be linked to BCG vaccination of younger people (below age 40yrs).


5. Human mobility as a confounder - Several countries have implemented social distancing and quarantines as the number of detected cases and fatalities have increased during the COVID-19 pandemic. Some countries benefit from extreme geographic isolation and this attenuates deaths independently (New Zealand). These countries have variable success in suppressing the increase in fatalities, with New Zealand being most successful, by exploiting its geographic isolation and the introduction of strong suppression measures it has extinguished this wave of the pandemic within its borders. Historical epidemiological studies, especially those dating to the Spanish Flu pandemic of 1918 have shown the levels of efficacy social distancing and quarantines have in reducing fatalities. These measures coupled to hand washing, mask wearing and general hygiene all attenuate the spread of the epidemic and thus suppress fatalities.⁴ Though not directly linked to mobility, the presence of physical infrastructure from prior pandemics weighs in favor of specific nations in the speed and efficacy of their responses, for example those of S. Korea (MERS) Taiwan (H1N1) and Hong Kong (SARS). Epidemiological models are effective in weighting the impact of these measures. Notably this variable should be independent enough of BCG status however in our data sample (there are suppression behaviors on either side of the high and low fatalities and on either side of the BCG status).

6. Other vaccines have been shown to elicit nonspecific protective effects highly similar to trained immunity. These include the oral polio vaccine (OPV)⁵, measles vaccine administered as MMR^{6,7} and vaccinia vaccine.⁸ The preponderance of the administration of these vaccines concurrently with BCG make their influence difficult to deconvolve at this time. However, we aim to address the trained immunity components in COVID-19 protection for these three important vaccines in forthcoming studies and publications. We analyzed in detail the preponderance of OPV vaccination and where such vaccination had occurred relative to BCG vaccination. These data are analyzed side-by-side with our BCG vaccination model. At this time it is complicated to deconvolute and quantify the contribution of each vaccine to protection from mortality. These data are reproduced in **Supplemental Table 3**.

7. Comorbidities of certain chronic diseases act as strong confounders and the contribution of BCG in neutralizing these is unclear. The CDC China identified cardiovascular disease, hypertension,

diabetes and obesity as the four key major comorbidities associated with COVID-19. Quantifying this alongside vaccination contribution should be part of ongoing research but many countries in our study also have low death per capita from COVID-19 and high rates of Diabetes, Heart Disease, Obesity. As we point out in this study, sufficient data to quantify *how much* protection is afforded by BCG vaccination will emerge in the coming months as more data points accrete in our model. This becomes very important when large populations which are HIV positive (which is immunosuppressive) are exposed to COVID-19. An important situation is that of South Africa with nearly 8 million HIV positive individuals but a mandatory BCG vaccination program that vaccinates within days after birth.

8. Urbanization as a confounder. Large urban centers with high populations may have an effect of amplifying the spread of the pandemic. This may occur through several means including lapses in social distancing that occur in transportation and work environments. To analyze the contribution of this confounder we used the top 20 regions of the world where the highest percentage of the population resides in urban areas as a proportion of total population². This analysis revealed that even amongst the strictly highest urbanized set of 20 countries the split between BCG vaccinated and unvaccinated remained apparent. **Supplemental Figure 4.**



Supplemental Figure 4: A number of studies have suggested urbanization and its corollary effects lead to the rapid spread of COVID-19 and subsequent high mortality rates. To account for confounding factors of COVID-19 mortality rates between BCG and nonBCG vaccinating countries we analyzed the top 20 urbanized regions. Clear separations between BCG vaccinated

and unvaccinated countries emerge suggesting that COVID-19 mortality is correlated with BCG vaccination status.


Supplemental note 2

Outliers


1. The case of Lebanon as an outlier, based on the graph in Figure 1, bears further investigation into the possible reasons for its strong proximity in its “slope” to BCG vaccinated countries. Lebanon has a population of approximately 6.1 million. This population was 4 million just a decade ago. This dramatic growth in just a decade is due to immigration from fleeing refugees from neighboring countries, in particular Syria. All neighboring countries have mandatory BCG programs and the policies of Lebanon coordinated with the WHO, UNICEF and NGOs was to vaccinate all refugees especially children prioritizing polio vaccination⁹. The Lebanese government emphasized the preservation of Lebanon as a polio free area, aggressively making sure that all refugees received oral polio vaccination (OPV) as well as MMR vaccination. BCG vaccination while conducted was not as heavily enforced. The most significant insight from the Lebanese COVID-19 fatality data is its relationship to OPV and MMR. As mentioned in Supplemental Note 1 point (7), both OPV⁵, and MMR^{6,7} are able to elicit nonspecific protective effects akin to trained immunity. Since BCG has been demonstrated to elicit its nonspecific protection by a similar mechanism we cannot exclude that Lebanon benefits from its mandatory coverage of OPV and MMR though we have insufficient data at this time to make this assertion confidently. Australia also has experienced a large relatively recent change in demographics which we found interesting (covered below).
2. The case of Portugal as an outlier is based on its high ranking in Table 1 in the low and medium confidence table, yet nominally being a BCG vaccinating country. A strong geographic proximity to Spain suggests the nonBCG vaccinated population would be larger, due to migratory trends between these countries. This is augmented by a large percentage of its population returned from former African colonies (Angola and Mozambique) in the mid-1970s (15% nearly 1 million individuals over two years) from countries with no BCG vaccination policy at that time. Therefore quantifying the long term compliance of BCG vaccination is difficult to assess. We do note that WHO records¹⁰ show 40 yrs ago there were no reported BCG vaccination numbers from Portugal and the earliest records from 1985 report 82% coverage.
3. The case of Ireland as an outlier is based on the graph in Figure 1 and bears further investigation into the possible reasons for its strong proximity in its “slope” to nonBCG vaccinated countries. While WHO records¹² of BCG vaccination do not extend further than 1980, some important events in the Irish record emerge including (reported in The Irish Times¹¹) a stockout beginning in 2015 of extended duration over multiple years. However, compliance in Ireland (Supplemental Figure 3) even prior to the stockout was dramatically low with reported levels as low as 34% 2004. Importantly as far back as 1980 Ireland did not report any active BCG vaccination until 1985 meaning it is possible that individuals over 40 yrs old in Ireland did not systematically receive BCG vaccinations and thereafter implementation of the policy was sporadic. See Supplemental Figure 3. How far back in time this lapse in compliance extends is data currently unavailable.
4. The case of Australia as an outlier is based on the graph in Figure 1 and bears further investigation into the possible reasons for its strong proximity in its “slope” to BCG vaccinated

countries, though it is nominally a nonBCG vaccinating country. It also appears in Table 1, and in Supplemental Table 1 as a significant outlier. It is an outlier because it has no universal BCG vaccination policy except for immigrants to Australia, children who have at least one parent who is an immigrant and Aboriginal peoples. Australia has one of the highest immigrant populations in the world, 29% of the population are immigrants. This creates a significant part of the population with BCG coverage in the population. Its geographic location, similar to New Zealand, may also work to attenuate spread of infection and indirectly reduce mortality rates.


5. The case of Norway as an outlier is based on Supplemental Table 1 . Norway was the last to give up universal BCG in 2009. Until then, all tuberculin-negative schoolchildren were vaccinated at the age of 12–14 years. In addition, both before and after 2009, vaccination was recommended for newborns with immigrant parents from high-incidence countries, for all students and employees <35 years of age in the healthcare sector, and for individuals <35 years of age planning a long-term stay in a country with high incidence of TB.¹²
- 6.



Supplemental Figure 2: Current BCG Vaccination programs worldwide as of April 2020,



Supplemental Figure 3: Current BCG strains used in vaccination programs worldwide.¹³



Supplemental Figure 5: Large disparities between Official (Irish government) reported BCG vaccination compliance and estimated vaccine coverage reported by the WHO using actual vaccine batches.

References:

1. COVID-19 Coronavirus Pandemic. Worldometers.
2. Roser M, Ritchie H, Ortiz-Ospina E. Coronavirus Disease (COVID-19) – Statistics and Research. Published online at OurWorldInDataorg Retrieved from: '<https://ourworldindata.org/coronavirus>' [Online Resource]. 2020.
3. Miller A, Reandelar MJ, Fasciglione K, Roumenova V, Li Y, Otazu GH. Correlation between universal BCG vaccination policy and reduced morbidity and mortality for COVID-19: an epidemiological study. medRxiv. 2020:2020.03.24.20042937.
4. Zhang J, Litvinova M, Liang Y, Wang Y, Wang W, Zhao S, et al. Changes in contact patterns shape the dynamics of the COVID-19 outbreak in China. *Science*. 2020:eabb8001.
5. Aaby P, Hedegaard K, Sodemann M, Nhante E, Veirum JE, Jakobsen M, et al. Childhood mortality after oral polio immunisation campaign in Guinea-Bissau. *Vaccine*. 2005;23(14):1746-51.
6. Aaby P, Martins CL, Garly ML, Bale C, Andersen A, Rodrigues A, et al. Non-specific effects of standard measles vaccine at 4.5 and 9 months of age on childhood mortality: randomised controlled trial. *BMJ*. 2010;341:c6495.
7. Mina MJ, Metcalf CJ, de Swart RL, Osterhaus AD, Grenfell BT. Long-term measles-induced immunomodulation increases overall childhood infectious disease mortality. *Science*. 2015;348(6235):694-9.
8. Blok BA, Jensen KJ, Aaby P, Fomsgaard A, van Crevel R, Benn CS, et al. Opposite effects of Vaccinia and modified Vaccinia Ankara on trained immunity. *Eur J Clin Microbiol Infect Dis*. 2019;38(3):449-56.
9. UNICEF. Evaluation of Immunisation Programme (EPI) in Lebanon (2013-2017).
10. WHO. Global Health Observatory data repository.
11. Times I. BCG may no longer be a routine vaccine for children - HSE.
12. Arnesen TM, Brantsaeter AB, Nokleby H. Bacille Calmette-Guerin vaccination of healthcare personnel: changing epidemiology calls for new recommendations in Norway. *Eur Respir J*. 2019;53(1).
13. Ritz N, Curtis N. Mapping the global use of different BCG vaccine strains. *Tuberculosis (Edinb)*. 2009;89(4):248-51.